GMA is the global / international marketing agency treating this city as a buyer-evaluation problem inside market-entry marketing. The work is the local-market website, proof order, offer language, SEO/AI visibility, paid path, and follow-up a foreign or outbound company needs before serious buyers move.
US marketing for medtech firms inside the BME and AIT ecosystem, industrial groups, and engineering-commercial owners headquartered in Vienna. The Austrian sales language and CEE-gateway position carry weight at home. They land as regional, not category-leading, abroad.
The Vienna business is real. Standing in the Austrian medtech and life-sciences cluster around BME, AIT, the Vienna BioCenter, and the Medical University of Vienna, the technical industrial base, and the engineering-commercial supplier tier has been earned over decades of delivery, regulatory cleanliness, and quiet compounding inside Austrian, German, and Central and Eastern European procurement. Revenue is validated. The decision is made to put weight into the US market. A US subsidiary opens, a US acquisition closes, a first US KOL relationship begins, or a portfolio company starts its American commercialisation. The first ninety days do not match the model. US meetings happen. US KOLs do not return calls. US commercial follow-up goes cold.
The instinct is to lead with the Vienna position as a Central European hub and a CEE gateway, which is a credible and accurate frame in Europe. The instinct is wrong for the American buyer. Austrian commercial culture signals seriousness through technical rigour, regional integration, and academic-industrial heritage. US commercial culture judges the CEE-gateway frame as a regional positioning rather than a category claim. The American KOL, US procurement officer, or US commercial partner does not interpret the gateway frame as scale. They interpret it as GMA placing itself in a regional bucket the US buyer does not have a category slot for.
American buyers sort fast on three signals: category anchor, outcome claim, and US peer set. Vienna materials tend to lead with regional position and engineering credential. The American buyer does not extract the category from regional framing. They move on. The work is to translate the Austrian identity and the Vienna anchor into US-legible category, outcome, and peer-set claims without hollowing out what carries at home.
The American KOL is not asking for fewer regional credentials. They are asking for the US category, the US outcome, and the US peer set. Vienna firms lead with the CEE frame and the engineering frame and never reach the first signal. House view on Vienna to US entry
The engineering is not the problem. The medical-device or industrial product is not the problem. The American-facing sales material is.
Six to ten weeks. Single US category, single corridor. GMA rebuilds positioning, price presentation, messaging, and proof and trust system for the American KOL, procurement, and commercial buyer, then launches it into market.
See the Sprint →Three to six months. Multi-channel US rebuild and run. Ads, website, search, sales pages, follow-up, and sales material. The standard shape for Vienna medtech and industrial owners committed to US scale.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across multiple US website, deck, and sales materials. Typical for Vienna medtech groups and family-office-backed portfolios with several US-facing brands or operating companies.
See the Partnership →No legal services. No Austrian company formation or US entity formation. No FMA licensing, no FDA or CE-mark regulatory submission, L-1, E-2, EB-5, or O-1 visa work. No US tax structuring, FATCA analysis, or double-tax-treaty analysis. No US banking introductions. No fiduciary services. No regulatory licensing. No IP filing. No contract drafting. No US clinical-trial design or site selection. No search-ranking or organic-discovery scope on this engagement surface.
These belong with Austrian counsel who specialise in US entry, US counsel on the American side, and clinical and regulatory specialists. GMA works inside the parameters they set. When a marketing decision carries legal, regulatory, or clinical implications, GMA flags it and defers before execution.
Vienna runs on engineering credentials, the medtech and life-sciences cluster around BME, AIT, and the Vienna BioCenter, and a CEE-gateway position that carries weight across Central and Eastern Europe. American buyers filter on category anchor, outcome claim, and US peer set before anything else. Vienna positioning that frames GMA as a Central European hub or CEE gateway lands as regional rather than category-leading to a US procurement, US KOL, or US commercial buyer. GMA does not change at the border. The buyer does. The correction is buyer-language translation, not identity replacement.
Medtech as the primary vertical, given the Vienna medical-device and life-sciences cluster. Industrials and engineering-commercial firms alongside. GMA also works with Vienna-based fiduciaries and specialists introducing international client companies to US operators. Fit is checked against the concrete US move, not published sector lists.
No. Austrian GmbH or AG formation, FMA licensing, FDA or CE-mark regulatory work, US LLC or C-corp formation, L-1, E-2, EB-5, and O-1 visa support, transfer pricing, US tax residency, and US banking introductions are handled by the owner's Austrian counsel and US counsel. GMA builds the US website, deck, proof, and follow-up around the legal and tax structure counsel already chose.
No. GMA does not pay referral fees to Vienna lawyers, tax specialists, or trust officers who introduce client companies. Introductions carry no referral fee. The fiduciary retains the relationship with the owner. GMA builds the US-facing website, deck, proof, and follow-up around the structure the specialist already manages. Fiduciary introductions route through partnerships@globalmarketing.agency.
With an inquiry through the contact form and an inquiry screening. GMA runs three engagements: Market-Entry Marketing Sprint (6 to 10 weeks), Cross-Border Marketing Build (3 to 6 months), or Global Marketing Partnership (monthly retainer, 12-month minimum). GMA confirms fit and pricing after the inquiry screening. Public prices are not listed.
Why precision language lands as process avoidance to US procurement, and what to rebuild before the next meeting.
Open the piece →City-by-city comparison of buyer-language problems and US-facing rebuilds across Dubai, Singapore, Hong Kong, Zurich, and London.
Evaluate the comparison →The wider DACH gate for operators in Germany, Austria, Switzerland, and Liechtenstein.
See the DACH gate →The operator-specific page for CEOs and commercial leads running a US subsidiary, US acquisition, or direct outbound from this corridor.
Operators in Vienna →Vienna and the wider Austria corridor produce timber systems, windows, building automation, and specialty hardware. Why Austrian building products do not transfer to the US specification chain and what the rebuild requires.
See the problem →The corridor splits into audience-specific routes. Open the route that matches the situation.
When Austrian proof needs a US hospital or procurement path.
Open the file →When CEE bridge credibility does not translate into the US buyer frame.
Open the file →When the export story fails a US RFP or RFQ even though the product is real.
Open the file →If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | The buyer should request a quote, ask for a call, send an RFQ, move a proposal forward, or hand the work to the right internal person. |
| What may be unclear | If that is not happening, the market may not understand the category, proof, offer, price, channel, service answer, or follow-up. |
| What to inspect | Check the page, sales deck, product proof, offer language, contact path, and follow-up before adding more traffic or more distributors. |
| Next step | If the break is commercial, continue to /engagements/ or /contact/#inquiry. |